Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07400952
Recruiting Phase 2

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

NCT07400952 · tracked via the Priya Life Science USA tracker
Sponsor
Glaukos Corporation
Phase
Phase 2
Started
2025-12-23
Last updated
2026-02-10

Condition(s) studied

Keratoconus

Investigational drug(s) / intervention(s)

GLK-221 Ophthalmic SolutionPlacebo Ophthalmic Solution

GLK-221 Ophthalmic Solution: GLK-221 Ophthalmic Solution administered twice daily to both eyes

Placebo Ophthalmic Solution: Placebo Ophthalmic Solution administered twice daily to both eyes

Study summary

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Be ≥ 18 and ≤ 55 years of age * Diagnosis of keratoconus in the study eye Exclusion Criteria: * Pregnant, lactating or planning a pregnancy * Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial

Primary outcome measure(s)

  • Mean change from baseline in maximum corneal curvature — 16 weeks
    Mean change from baseline in maximum corneal curvature

Trial sites (1)

FacilityCityRegionStatus
Glaukos Clinical Study Site Westerville Ohio Recruiting

More Glaukos Corporation trials in the USA

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus Recruiting
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg Recruiting
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone Recruiting
iDose TR Administration in an Office-Based Surgery Setting Recruiting
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Recruiting

Other trials for the same condition

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus Recruiting
Assessing Patient Engagement in Keratoconus Clinical Research Starting soon
McNeel Eye Center Corneal Crosslinking Study Active, not recruiting
Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07400952 on ClinicalTrials.gov ↗ ← All trials in the USA